Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
On the heels of a phase 3 win that failed to impress investors, Ironwood Pharmaceuticals is back with more data in efforts to prove that its long-acting GLP-2 analog can do more than beat placebo.